Omnicell, Inc. $OMCL Shares Purchased by Quantbot Technologies LP

Key Points

• Quantbot Technologies LP increased its position in Omnicell, Inc. by 64.5% during the first quarter, owning 41,819 shares valued at $1.46 million.
• Several institutions have made new acquisitions in Omnicell's stock, with institutional investors owning approximately 97.70% of the company's shares.
• Omnicell's shares have experienced a price target adjustment, with Wells Fargo raising it to $40.00, while other analysts have set targets between $34.00 and $62.00, leading to a consensus rating of "Moderate Buy."

Quantbot Technologies LP increased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 64.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,819 shares of the company's stock after buying an additional 16,397 shares during the period. Quantbot Technologies LP owned about 0.09% of Omnicell worth $1,462,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its position in Omnicell by 52.6% during the first quarter. Wellington Management Group LLP now owns 496,680 shares of the company's stock worth $17,364,000 after acquiring an additional 171,116 shares during the last quarter. Algert Global LLC raised its position in Omnicell by 278.0% during the first quarter. Algert Global LLC now owns 78,032 shares of the company's stock worth $2,728,000 after acquiring an additional 57,390 shares during the last quarter. Redmond Asset Management LLC raised its position in Omnicell by 16.4% during the first quarter. Redmond Asset Management LLC now owns 141,111 shares of the company's stock worth $4,933,000 after acquiring an additional 19,902 shares during the last quarter. Liontrust Investment Partners LLP raised its position in Omnicell by 7.3% during the first quarter. Liontrust Investment Partners LLP now owns 175,655 shares of the company's stock worth $6,141,000 after acquiring an additional 11,981 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Omnicell during the first quarter worth about $448,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Trading Down 0.6%

OMCL stock traded down $0.21 on Thursday, hitting $33.02. 109,372 shares of the company were exchanged, compared to its average volume of 566,842. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The business's fifty day moving average is $29.88 and its two-hundred day moving average is $31.75. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of 65.95, a price-to-earnings-growth ratio of 7.15 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. During the same quarter in the prior year, the business posted $0.51 earnings per share. Omnicell's revenue for the quarter was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Benchmark cut their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Bank of America lifted their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wells Fargo & Company lifted their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Finally, Piper Sandler cut their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $46.71.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.